Company news

Climb Bio, Inc. news in 2025

Climb Bio, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Climb Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(4)

November 26, 2025

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 25, 2025

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 6, 2025

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People and Workforce Strategy

October 22, 2025

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

October 21, 2025

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

October 17, 2025

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

October 1, 2025

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

September 29, 2025

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

September 4, 2025

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

August 25, 2025

Climb Bio to Present at Upcoming September 2025 Investor Conferences

August 25, 2025

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

August 19, 2025

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 12, 2025

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

June 18, 2025

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

April 1, 2025

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

March 27, 2025

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

March 25, 2025

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

February 24, 2025

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

January 8, 2025

Decks in 2025